Alumis publishes corporate deck on next-generation TYK2 inhibitors for immune-mediated diseases
ALMS•Corporate deck highlights TYK2 pipeline and development timelines
- Alumis highlighted Phase 3 psoriasis efficacy for envudeucitinib, citing Week 24 PASI 100 of 41% in ONWARD1, 39.5% in ONWARD2.
- Long-term extension ONWARD3 showed 48-week PASI 90 of 75% and PASI 100 of 54% in 773 patients.
- NDA filing for envudeucitinib in plaque psoriasis targeted for 4Q 2026.
- Potentially pivotal Phase 2b systemic lupus erythematosus topline data expected in 3Q 2026.
- A-005 Phase 2 biomarker trial initiation in Parkinson’s disease planned for 1H 2027.
